Navigation Links
Genomic Health Announces Initiation of Clinical Validation Study of Prostate Cancer Test; Acceleration of Next Generation Sequencing Program
Date:1/9/2012

REDWOOD CITY, Calif., Jan. 9, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it has started a large clinical validation study of its prostate cancer test.  The study, being performed in collaboration with leading prostate cancer researchers at the University of California, San Francisco (UCSF), is designed to determine if a multi-gene test can help distinguish aggressive disease requiring surgery from less aggressive disease that may undergo active surveillance in patients with early-stage prostate cancer. The study will utilize Genomic Health's proprietary RT-PCR process for analyzing very small amounts of formalin-fixed paraffin-embedded (FFPE) prostate tissue obtained by needle biopsy prior to removal of the prostate. Complete results are expected to be presented at the end of this year or early next year, and if positive, are expected to support the launch of the Oncotype DX® prostate cancer test in 2013.

"Moving our prostate cancer test into the final stage of clinical validation, combined with the recent successful launch of our Oncotype DX DCIS Score and MMR colon cancer testing service, reflects our ability to deliver better outcomes for cancer patients," said Kim Popovits, President and Chief Executive Officer, Genomic Health.  "Once validated, we believe the Oncotype DX prostate cancer test will provide physicians and prostate cancer patients with much needed information for making treatment decisions, similar to what our tests for breast and colon cancer do today."

The company also announced that it is accelerating its Next Generation Sequencing (NGS) program by moving it into clinical development studies that will examine both RNA-Seq expression and mutation analysis. This decision comes after the company successfully conducted the first clinical outcomes study for biomarker discovery u
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Genomic Health Announces Positive Results of First Clinical Outcomes Study for Biomarker Discovery Using Next Generation Sequencing at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
5. Genomic Health to Present at the Piper Jaffray Health Care Conference
6. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
7. Genomic Health Announces Third Quarter 2011 Financial Results and Business Progress
8. Everist Genomics Announces Acquisition of Angiologix, Inc.
9. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
10. Genomic Health to Present at the JMP Securities Healthcare Conference
11. Transgenomic to Present at Rodman & Renshaw 13th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... Johnson Pharmaceutical,Research & Development, L.L.C. (J&JPRD), today ... doripenem for injection), a,carbapenem antibiotic, was found ... certain,strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases,(ESBLs) than ... a large group of bacteria that can ...
... Data Shows Long-term Improvements in Productivity, Quality of ... American College ... Oct. 27 5:00 AM PST -- UCB announced,today ... pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor),- ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... The ability of the commonly used stimulant methylphenidate (Ritalin) ... both to the inhaled gas isoflurane, as previously reported, ... the same Massachusetts General Hospital (MGH) research team that ... propofol in the May issue of Anesthesiology, ...
... Reporter , THURSDAY, April 5 (HealthDay News) -- Exposure ... eaten by U.S. consumers is linked to shorter pregnancies ... are known as organophosphates, which kill insects by disrupting ... poisons during World War II, they can disrupt human ...
... Reporter , THURSDAY, April 5 (HealthDay News) -- Developing stem ... tumors has been one of the biggest challenges for stem ... of Philadelphia have generated a new line of stem cells ... destined for the digestive system or possibly the lungs. ...
... children undergoing early-stage surgery for single-ventricle heart defects, ... neurodevelopmental outcomes at 14 months of age. Instead, ... general medical morbidity during the child,s first year ... left-heart syndrome (HLHS) and related single-ventricle defects have ...
... ORANGE, N.J. April 4, 2012. John Whyte, MD, PhD, is ... Award for Excellence in Research and Education in the Field ... honored at the Foundation,s Board of Trustees dinner in West ... grant for Dr. Whyte,s research activities. Dr. ...
... Researchers reporting in the April Cell Stem Cell , ... leukemia stem cells in their tracks. The advance in mice ... chronic myeloid leukemia (CML) for good. That,s in contrast ... imatinib (aka Gleevec) today, who often go into remission only ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
... is the most advanced means of documenting ... management system that acquires extremely high quality ... can be captured directly from slit lamps ... well as any other ophthalmic device with ...
... device that replaces the old technology, the ... by bringing virtually unlimited charts to the ... are at the practitioners finger tips. The ... charts, optotypes, associated vision tests and fixation ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
... Two mirrored surfaces, which each incline ... front surface, have been cut into the ... it possible to examine the opposite iridocorneal ... expanse and form of the angle of ...
Medicine Products: